The COX-2 selective inhibitor,
valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
The committee recommended that celecoxib and
valdecoxib may remain on the market with black box warnings regarding the cardiovascular risks.
Rofecoxib was voluntarily withdrawn from the market in September 2004 and
valdecoxib was withdrawn in April of 2005, and these events affected physician prescribing habits.
NSAIDs such as
valdecoxib are known to provide effective analgesia when used for dysmenorrhoea1.
Ott E, Nussmeier NA, Duke PC 2003 Efficacy and safety of the cyclo-oxygenase 2 inhibitors parecoxib and
valdecoxib in patients undergoing coronary bypass surgery Journal of Thoracic and Cardiovascular Surgery 125 1481-1492
75 [micro]g/ml of TAM and 2 [micro]g/ml of
valdecoxib as internal standard.
Rofecoxib and
valdecoxib, highly selective COX-2 inhibitors, were recently withdrawn from the market because of adverse effects.
3) Another meta-analysis of two trials in high-risk patients taking
valdecoxib who had recently undergone coronary artery bypass surgery, showed a significant 3-fold increase in cardiovascular events.
Ever since reports of sudden heart attack and stroke prompted rofecoxib (Vioxx) and
valdecoxib (Bextra) to be taken off the market, other nonsteroidal anti-inflammatory drugs (NSAIDs) have been living under a shadow.
Evaluation of preemptive
valdecoxib therapy on initial archwire placement discomfort in adults.
Food and Drug Administration, Pfizer withdrew another COX-2 drug,
valdecoxib Bextra), from the market after studies showed an increased risk of heart attack, stroke and other cardiovascular problems in people taking the drug for postoperative pain after coronary artery bypass surgery.
In November 2001, the FDA granted approval to Pfizer for its COX-2 inhibitor
valdecoxib (Bextra) for three uses (menstrual pain, rheumatoid arthritis, and osteoarthritis), but rejected its application for acute pain.
